SCN3A: IHC Expression in Cancer and Radioligand Target Profile
SCN3A, sodium voltage-gated channel alpha subunit 3, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SCN3A staining is highest in colorectal cancer (100% of samples positive), prostate cancer (92% of samples positive) and head and neck cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).
Is SCN3A the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze SCN3A freeIs SCN3A a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SCN3A IHC staining by cancer type
Protein expression of SCN3A across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 0.58 | High | 100% |
| Prostate Cancer | 0.58 | High | 92% |
| Head and Neck Cancer | 0.50 | Medium | 100% |
| Testicular Cancer | 0.47 | Medium | 83% |
| Endometrial Cancer | 0.47 | Medium | 90% |
| Ovarian Cancer | 0.44 | Medium | 75% |
| Gastric Cancer | 0.41 | Medium | 89% |
| Bladder Cancer | 0.39 | Medium | 82% |
| Skin Cancer | 0.36 | Medium | 73% |
| Melanoma | 0.36 | Medium | 64% |
| Pancreatic Cancer | 0.36 | Medium | 64% |
| Breast Cancer | 0.33 | Medium | 73% |
| Neuroendocrine Tumors | 0.33 | Medium | 50% |
| Thyroid Cancer | 0.33 | Medium | 33% |
| Glioma | 0.30 | Medium | 55% |
| Lung Cancer | 0.27 | Medium | 60% |
| Liver Cancer | 0.22 | Medium | 42% |
| Cervical Cancer | 0.13 | Low | 30% |
| Lymphoma | 0.06 | Low | 17% |
| Kidney Cancer | 0.06 | Low | 8% |
Is SCN3A internalized?
Nuclens has not yet extracted internalization evidence for SCN3A. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
SCN3A clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for SCN3A yet. Search ClinicalTrials.gov for SCN3A trials.
SCN3A normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SCN3A in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SCN3A gene essentiality (DepMap)
CRISPR knockout effect across 1251 cancer cell lines: 0.07 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how SCN3A ranks against 15,000 targets for your indication.
Analyze SCN3A freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.